Aspirin and Asthma

      Aspirin is not only one of the best-documented medicines in theworld, but also one of the most frequently used drugs of all times. Inaddition to its role as an analgesic, aspirin is being increasinglyused in the prophylaxis of ischemic heart disease and strokes. Theprevalence of aspirin intolerance is around 5 to 6%. Up to 20% of theasthmatic population is sensitive to aspirin and other nonsteroidalanti-inflammatory drugs (NSAIDs) and present with a triad of rhinitis,sinusitis, and asthma when exposed to the offending drugs. Thissyndrome is referred to as aspirin-induced asthma (AIA).The pathogenesis of AIA has implicated both the lipoxygenase (LO) andthe cyclooxygenase (COX) pathways. By inhibiting the COX pathway,aspirin diverts arachidonic acid metabolites to the LO pathway. Thisalso leads to a decrease in the levels of prostaglandin (PG)E2, the anti-inflammatory PG, along with an increase in thesynthesis of cysteinyl leukotrienes (LTs). Evidence suggeststhat patients with AIA have increased activity of LTC4synthase, the rate-limiting enzyme in the cysteinyl LT synthesis, intheir bronchial biopsy specimens, thereby tilting the balance in favorof inflammation. LT-modifying drugs are effective in blocking thebronchoconstriction provoked by aspirin and are used in the treatmentof this condition. Aspirin desensitization has a role in the managementof AIA, especially in patients who need prophylaxis from thromboembolicdiseases, myocardial infarction, and stroke. This review covers thelatest understanding of pathogenesis, clinical features, and managementof AIA.

      Key words


      AIA (aspirin-induced asthma), ASA (acetylsalicylic acid), ATA (aspirin-tolerant asthma), COX (cyclooxygenase), CSS (Churg-Strauss syndrome), IL (interleukin), LO (lipoxygenase), LT (leukotriene), NSAID (nonsteroidalanti-inflammatory drug), PG (prostaglandin)
      To read this article in full you will need to make a payment
      Subscribe to CHEST
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Widal MF
        • Abrami P
        • Lenmoyez J
        Anaphylaxie et idiosyncrasie.
        Presse Med. 1922; 30: 189-192
        • Spector SL
        • Wangaard CH
        • Farr RS
        Aspirin and concomitant idiosyncrasies in adult asthmatic patients.
        J Allergy Clin Immunol. 1979; 64: 500-506
        • Sturtevant J
        NSAID-induced bronchospasm: a common and serious problem; a report from MEDSAFE, the New Zealand medicines and medical devices safety authority.
        NZ Dent J. 1999; 95: 84
        • Hedman J
        • Kaprio J
        • Poussa T
        • et al.
        Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study.
        Int J Epidemiol. 1999; 28: 717-722
        • Schlumberger HD
        Drug-induced pseudo-allergic syndrome as exemplified by acetyl salicylic acid intolerance.
        in: Dukor P Kallos P Schlumberger HD Involvement of drugs and chemicals. Karger, Basel, Switzerland1980: 125-180
        • Christie PE
        • Smith CM
        • Lee TH
        The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma.
        Am Rev Respir Dis. 1991; 144: 957-958
        • Christie PE
        • Tagari P
        • Ford-Hutchinson AW
        • et al.
        Urinary leukotriene E4 after lysine-aspirin inhalation in asthmatic subjects.
        Am Rev Respir Dis. 1992; 146: 1531-1534
        • Sladek K
        • Dworski R
        • Soja J
        • et al.
        Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with asthma after aspirin challenge.
        Am J Respir Crit Care Med. 1994; 149: 940-946
        • Cowburn AS
        • Sladek K
        • Soja J
        • et al.
        Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma.
        J Clin Invest. 1998; 101: 834-846
        • Penrose JF
        • Spector J
        • Baldasaro M
        • et al.
        Molecular cloning of the gene for human leukotriene C4 synthase: organization, nucleotide sequence, and chromosomal localization to 5q35.
        J Biol Chem. 1996; 271: 11356-11361
        • Sanak M
        • Simon HU
        • Szczeklik A
        Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma.
        Lancet. 1997; 350: 1599-1600
        • Szczeklik A
        • Stevenson DD
        Aspirin-induced asthma: advances in pathogenesis and management.
        J Allergy Clin Immunol. 1999; 104: 5-13
        • In KH
        • Asano K
        • Beier D
        • et al.
        Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription.
        J Clin Invest. 1997; 99: 1130-1137
        • Holgate ST
        • Burns GB
        • Robinson C
        • et al.
        Anaphylactic- and calcium-dependent generation of prostaglandin D2 (PGD2), thromboxane B2, and other cyclooxygenase products of arachidonic acid by dispersed human lung cells and relationship to histamine release.
        J Immunol. 1984; 133: 2138-2144
        • Churchill L
        • Chilton FH
        • Resau JH
        • et al.
        Cyclooxygenase metabolism of endogenous arachidonic acid by cultured human tracheal epithelial cells.
        Am Rev Respir Dis. 1989; 140: 449-459
        • Sousa A
        • Pfister R
        • Christie PE
        • et al.
        Enhanced expression of cyclo-oxygenase isoenzyme 2 (COX-2) in asthmatic airways and its cellular distribution in aspirin-sensitive asthma.
        Thorax. 1997; 52: 940-945
        • Szczeklik A
        • Sladek K
        • Dworski R
        • et al.
        Bronchial aspirin challenge causes specific eicosanoid response in aspirin-sensitive asthmatics.
        Am J Respir Crit Care Med. 1996; 154: 1608-1614
        • Mitchell JA
        • Belvisi MG
        Too many COX (cyclo-oxygenase) spoil the broth: aspirin-sensitive asthma and 5-lypoxygenase.
        Thorax. 1997; 52: 933-935
        • Nasser SM
        • Pfister R
        • Christie PE
        • et al.
        Inflammatory cell populations in bronchial biopsies from aspirin- sensitive asthmatic subjects.
        Am J Respir Crit Care Med. 1996; 153: 90-96
        • Martin TR
        • Goodman RB
        The role of lung mononuclear cells in asthma, allergy and bronchial hyperresponsiveness.
        Immunol Allergy Clin North Am. 1990; 10: 295-308
        • Sousa AR
        • Lams BE
        • Pfister R
        • et al.
        Expression of interleukin-5 and granulocyte-macrophage colony- stimulating factor in aspirin-sensitive and non-aspirin-sensitive asthmatic airways.
        Am J Respir Crit Care Med. 1997; 156: 1384-1389
        • Szczeklik A
        Aspirin-induced asthma as a viral disease.
        Clin Allergy. 1988; 18: 15-20
        • Levy M
        Role of viral infections in the induction of adverse drug reactions.
        Drug Saf. 1997; 16: 1-8
        • Yoshida S
        • Sakamoto H
        • Yamawaki Y
        • et al.
        Effect of acyclovir on bronchoconstriction and urinary leukotriene E4 excretion in aspirin-induced asthma.
        J Allergy Clin Immunol. 1998; 102: 909-914
        • Samter M
        • Beers RFJ
        Intolerance to aspirin: clinical studies and consideration of its pathogenesis.
        Ann Intern Med. 1968; 68: 975-983
        • Stevenson DD
        • Simon RA
        Sensitivity to aspirin and non-steroidal anti-inflammatory drugs.
        in: Middleton EJ Reed CE Ellis EF Allergy principles and practice. Mosby Year Book, St. Louis, MO1998: 1747-1765
        • Marquette CH
        • Saulnier F
        • Leroy O
        • et al.
        Long-term prognosis of near-fatal asthma: a 6-year follow-up study of 145 asthmatic patients who underwent mechanical ventilation for a near- fatal attack of asthma.
        Am Rev Respir Dis. 1992; 146: 76-81
        • Patriarca G
        • Venuti A
        • Bonini W
        Allergy to pyramidon (aminopyrine).
        Ann Allergy. 1973; 31: 84-86
        • Szczeklik A
        • Greglewski RJ
        • Czerniawska-Mysik GR
        Clinical patterns of hypersensitivity to nonsteroidal anti-inflammatory drugs and their pathogenesis.
        J Allergy Clin Immunol. 1977; 60: 276-284
        • Milewski M
        • Mastalerz L
        • Nizankowska E
        • et al.
        Nasal provocation test with lysine-aspirin for diagnosis of aspirin- sensitive asthma.
        J Allergy Clin Immunol. 1998; 101: 581-586
        • Settipane RA
        • Schrank PJ
        • Simon RA
        • et al.
        Prevalence of cross-sensitivity with acetaminophen in aspirin-sensitive asthmatic subjects.
        J Allergy Clin Immunol. 1995; 96: 480-485
        • Bianco S
        • Robuschi M
        • Petrigni G
        • et al.
        Efficacy and tolerability of nimesulide in asthmatic patients intolerant to aspirin.
        Drugs. 1993; 46: 115-120
        • Kosnik M
        • Music E
        • Matjaz F
        • et al.
        Relative safety of meloxicam in NSAID-intolerant patients.
        Allergy. 1998; 53: 1231-1233
        • Szczeklik A
        • Nizankowska E
        • Czerniawska-Mysik G
        • et al.
        Hydrocortisone and airflow impairment in aspirin-induced asthma.
        J Allergy Clin Immunol. 1985; 76: 530-536
        • Feigenbaum BA
        • Stevenson DD
        • Simon RA
        Hydrocortisone sodium succinate does not cross-react with aspirin in aspirin-sensitive patients with asthma.
        J Allergy Clin Immunol. 1995; 96: 545-548
        • Drazen JM
        • Israel E
        • O'Byrne PM
        Treatment of asthma with drugs modifying the leukotriene pathway.
        N Engl J Med. 1999; 340: 197-206
        • Israel E
        • Fischer AR
        • Rosenberg MA
        • et al.
        The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin.
        Am Rev Respir Dis. 1993; 148: 1447-1451
        • Pauls JD
        • Simon RA
        • Daffern P
        • et al.
        Effectiveness of the 5-LO inhibitor zileuton during oral challenges in aspirin-sensitive asthmatics [abstract].
        J Allergy Clin Immunol. 1999; 103: S229
        • Dahlen B
        • Nizankowska E
        • Szczeklik A
        • et al.
        Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics.
        Am J Respir Crit Care Med. 1998; 157: 1187-1194
        • Kuna P
        • Malmstrom K
        • Dahlen SE
        • et al.
        Montelucast (MK-0476) a CysLT1 receptor antagonist improves asthma control in aspirin-intolerant asthmatic patients [abstract].
        Am J Respir Crit Care Med. 1997; 155: A975
        • Rosenwasser LJ
        Leukotriene modifiers: new drugs, old and new reactions.
        J Allergy Clin Immunol. 1999; 103: 374-375
        • Wechsler ME
        • Pauwels R
        • Drazen JM
        Leukotriene modifiers and Churg-Strauss syndrome: adverse effect or response to corticosteroid withdrawal?.
        Drug Saf. 1999; 21: 241-251
        • Szczeklik A
        • Dworski R
        • Mastalerz L
        • et al.
        Salmeterol prevents aspirin-induced attacks of asthma and interferes with eicosanoid metabolism.
        Am J Respir Crit Care Med. 1998; 158: 1168-1172
        • Pleskow WW
        • Stevenson DD
        • Mathison DA
        • et al.
        Aspirin desensitization in aspirin-sensitive asthmatic patients: clinical manifestations and characterization of the refractory period.
        J Allergy Clin Immunol. 1982; 69: 11-19
        • Szmidt M
        • Grzelewska-Rzymowska I
        • Rozniecki J
        Tolerance to aspirin in aspirin-sensitive asthmatics: methods of inducing the tolerance state and its influence on the course of asthma and rhinosinusitis.
        J Invest Allergol Clin Immunol. 1993; 3: 156-159
        • Nasser SM
        • Patel M
        • Bell GS
        • et al.
        The effect of aspirin desensitization on urinary leukotriene E4 concentrations in aspirin-sensitive asthma.
        Am J Respir Crit Care Med. 1995; 151: 1326-1330
        • Sweet JM
        • Stevenson DD
        • Simon RA
        • et al.
        Long-term effects of aspirin desensitization–treatment for aspirin-sensitive rhinosinusitis-asthma.
        J Allergy Clin Immunol. 1990; 85: 59-65
        • Stevenson DD
        • Hankammer MA
        • Mathison DA
        • et al.
        Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: long-term outcomes.
        J Allergy Clin Immunol. 1996; 98: 751-758
        • Patriarca G
        • Schiavino D
        • Nucera E
        • et al.
        Prevention of relapse in nasal polyposis [letter].
        Lancet. 1991; 337: 1488
        • Schmitz-Schumann M
        • Menz G
        • Kohl C
        • et al.
        Adaptive desaktivierung bei analgetika-asthma syndrom: methodik und phanomene der toleranzinduktion.
        Prax Klin Pneumol. 1985; 39: 868-869
        • Schaefer OP
        • Gore JM
        Aspirin sensitivity: the role for aspirin challenge and desensitization in postmyocardial infarction patients.
        Cardiology. 1999; 91: 8-13
        • Juergens UR
        • Christiansen SC
        • Stevenson DD
        • et al.
        Inhibition of monocyte leukotriene B4 production after aspirin desensitization.
        J Allergy Clin Immunol. 1995; 96: 148-156
        • Arm JP
        • O'Hickey SP
        • Spur BW
        • et al.
        Airway responsiveness to histamine and leukotriene E4 in subjects with aspirin-induced asthma.
        Am Rev Respir Dis. 1989; 140: 148-153
        • Grzelewska-Rzymowska I
        • Szmidt M
        • Rozniecki J
        • et al.
        Aspirin-induced neutrophil chemotactic activity (NCA) in patients with aspirin-sensitive urticaria after desensitization to the drug.
        J Invest Allergol Clin Immunol. 1994; 4: 28-31
        • Salazar Villa RM
        • Zambrano Villa S
        Asthma induced by aspirin and arachidonic acid metabolites: role of leukotrienes (third part).
        Rev Alerg Mex. 1994; 41: 51-57